345 Urticaria, Angioedema, and Allergic Rhinitis Flashcards
The binding of IgE to human mast cells and basophils is termed: (H20 C345 P2498)
Sensitization
The predominant mast cell prostanoid (H20 C345 P2499)
Prostaglandin D2
Most potent known bronchoconstrictor (H20 C345 P2499)
Leukotriene D4
Levels of this enzyme are inversely related to the severity of anaphylaxis (H20 C345 P2499)
PAF acetyl hydrolase
Receptor for stem cell factor (H20 C345 P2499)
c-kit
Key effector cells in allergic rhinitis and asthma (H20 C345 P2498)
Mast cells
Lipid mediator of neutrophil chemotaxis (H20 C345 P2500)
Leukotriene B4
Antigen-presenting cells of monocytic lineage that processes allergens (H20 C345 P2500)
Dendritic cells
Level of skin involved in urticaria (H20 C345 P2500)
Superficial dermis
Duration of acute urticaria/angioedema (H20 C345 P2500)
<6 weeks
Most common age group for chronic urticaria/angioedema (H20 C345 P2500)
3rd to 5th decade
Peak prevalence of dermatographism (H20 C345 P2501)
2nd-3rd decades
Distinctive size of wheals in cholinergic urticaria (H20 C345 P2501)
1-2 mm
Physical urticaria that often accompanies chronic idiopathic urticaria (H20 C345 P2501)
Pressure urticaria
Exercise-induced anaphylaxis is associated with the presence of IgE specific for this component of wheat (H20 C345 P2501)
α-5 gliadin
Most common sites for angioedema (H20 C345 P2501)
Periorbital, perioral
Hereditary angioedema is caused by a mutation in this gene (H20 C345 P2502)
SERPING1
Indication for biopsy of urticarial lesion (H20 C345 P2502)
Lasts longer than 36 h, result in scarring, painful and not pruritic
Chronic angioedema with urticaria warrants assessment of: (H20 C345 P2502)
Complement levels
Concomitant flushing and hyperpigmented papules that urticate with stroking in the absence of angioedema raise the question of: (H20 C345 P2502)
Mastocytosis
Gene mutation involved in type 3 HAE (H20 C345 P2502)
Factor XII
Add-on therapy for chronic idiopathic urticaria that is severe and poorly responsive to other therapies or when glucocorticoids are a requirement (H20 C345 P2502)
Cyclosporine
Bradykinin 2 receptor agonist used to treat acute attacks of HAE (H20 C345 P2502)
Icatibant
Kallikrein inhibitor used for treatment of acute attacks of HAE (H20 C345 P2502)
Ecallantide
Preoperative prophylaxis for HAE (H20 C345 P2502)
Ɛ-aminocaproic acid
Age group of peak prevalence of allergic rhinitis (H20 C345 P2502)
5th decade
Characterized by nasal obstruction, anosmia, chronic sinusitis, prominent eosinophilic nasal discharge in the absence of allergen sensitization (H20 C345 P2503)
Perennial nonallergic rhinitis with eosinophilia syndrome
Aside from pregnancy, what endocrinologic abnormality must be ruled out in the workup of allergic rhinitis (H20 C345 P2503)
Hypothyroidism
Symptom of allergic rhinitis that is NOT relieved by antihistamines (H20 C345 P2505)
Nasal congestion
Most potent drugs available for the relief of established rhinitis (H20 C345 P2505)
Intranasal high-potency glucocorticoids
Most frequent side effect of intranasal high-potency glucocorticoids (H20 C345 P2505)
Local irritation
Adverse effect of azelastine nasal spray (H20 C345 P2505)
Dysgeusia
Mechanism of action of cromolyn sodium (H20 C345 P2505)
Inhibits mast cell degranulation
Add-on therapy for persistent rhinorrhea in severe rhinitis (H20 C345 P2505)
Topical ipratropium
